spacer
home > ebr > spring 2007 > life after death
PUBLICATIONS
European Biopharmaceutical Review

Life after Death

Ann-Christin Malmborg Hager and Christina Furebring at Alligator Bioscience AB and Philippe Stas at AlgoNomics look at a growing trend for resuscitating abandoned clinical trials

Developing pharmaceuticals is a risky business, involving enormous costs. While pharmaceutical companies invest heavily in those molecules they believe in, a failure during the development process can be very damaging. According to several reports, only 10 per cent of drug candidates entering the preclinical phase will reach the market; what happens to the rest? Do the remaining 90 per cent that do not make it to the market forever inhabit the drug companies’wastepaper baskets? This article discusses a project that is put back on track after a failure in Phase I.

THE CHIPS PROTEIN

The drug candidate in question was chemotaxis inhibitory protein of Staphylococcus aureus (CHIPS) (1). The protein was discovered by the research group of Jos van Strijp, Professor of Microbiology at the Eijkman Winkler Institute in Utrecht, the Netherlands.

When bacteria enter the human body they are surrounded by human proteins. One of these proteins is C5a, a component of the complement system. C5a binds to the C5a receptor (C5aR), which is found on the surface of, for example, neutrophils, a very important cell type in the innate immune system. This activates the neutrophils, while stimulating chemotaxis so that more inflammatory cells are recruited to the site of infection.

To protect themselves, bacteria – in this case Staphylococci – develop mechanisms to prevent themselves from being destroyed by the recruited neutrophils (2). One mechanism used by Staphylococci is the production of a 14kD protein (the CHIPS protein) that downregulates the ability of C5aR to bind its ligands, by blocking the binding site of C5a. This blocks neutrophil chemotaxis.

The plan was to use CHIPS, with its anti-inflammatory effects, as a drug, preventing the progression of neutrophil-mediated inflammation that gives rise to and aggravates disease symptoms. In indications involving acute cases of inflammation, the effects of CHIPS could be beneficial, and at present there are no drugs on the market for such indications. The mechanism of CHIPS´ antiinflammatory ability is schematically outlined in Figure 1.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Dr Ann-Christin Malmborg Hager is Vice President of Business Development at Alligator Bioscience AB and holds a PhD in Immunotechnology from Lund University. She is one of the inventors of the Alligator proprietary technology, FIND®, and a founder of the company. Prior to joining Alligator, Ann-Christin held a position at Lund University and held a post-doctoral position at the University of California, Davis.

Dr Christina Furebring is Vice President of Research and Development at Alligator Bioscience AB, and holds a PhD in Immunotechnology from Lund University. She is also one of the inventors of the Alligator proprietary technology, FIND®, and a founder of the company. Christina previously held a position at Lund University and held a post-doctoral position at the University of Utrecht, the Netherlands.

Philippe Stas, Chief Operating Officer at AlgoNomics since 1990, has been involved in antibody engineering, immunology and bioinformatics research at the University of Brussels. After working as IT Manager for PE Genscope, he joined the team that created AlgoNomics in 1999. Philippe is president of the Belgian Association for Bioindustries.

spacer
Dr Ann-Christin Malmborg Hager
spacer
spacer
spacer
Dr Christina Furebring
spacer
spacer
spacer
Philippe Stas
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPhI expert forecasts ‘huge growth in Middle East manufacturing with Europe a medium-term target’

CPhI Middle East & Africa (CPhI MEA) expert Madhukar Tanna, Chief Executive Officer of Pharmax, a United Arab Emirates (UAE) based branded generic manufacturer, says favourable conditions in the UAE are resulting in a boom of pharmaceutical manufacturing throughout the region. Government incentive schemes to increase domestic production, coupled with a brand friendly environment and rising healthcare needs is fuelling surging demand – with many new companies and plants launching in the last two years alone.
More info >>

White Papers

PhlexEarchive: The Right Solution for Electronic Archiving of TMF Content

Phlexglobal Ltd

Many sponsor organizations have already recognized the value of moving from paper to electronic Trial Master Files (eTMFs). But few sponsors have taken a more holistic approach to the TMF lifecycle and looked at the entire process from study start-up through archiving of the TMF in electronic format, also known as e-archiving. The recurring value of managing, tracking, maintaining and accessing electronic files should not stop at the point of archiving. All of the challenges of managing an active paper TMF carry through to a paper archive. All of the benefits of an electronic TMF also carry through to the electronic archive. As companies look to move their compliance assets to secure, long-term storage, it is important to consider ongoing compliance requirements, security, accessibility, efficiency and costs of archiving TMF content in a digital format.
More info >>

 
Industry Events

Multimodal 2019

18-20 June 2019, NEC, Birmingham, UK

Now in its twelfth year, Multimodal is the UK and Ireland’s premier freight transport, logistics and supply chain management event.  Shippers and cargo owners attend to improve their businesses; by finding ways of moving their products more efficiently and by meeting new suppliers. 
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement